Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
Top Page
Shanghai Fosun Pharmaceutical (Group) Co
(2196)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$20.00
▲(1.88% Upside)
Action:ReiteratedDate:12/30/25
The score is held back primarily by weak cash conversion and deteriorating growth/return profile, alongside bearish technical momentum. A moderate P/E and modest dividend provide some valuation support, but not enough to outweigh the cash-flow and trend concerns.
Positive Factors
Oncology Innovation
The initiation of a Phase I trial for a PSMA-targeting radiopharmaceutical enhances Fosun Pharma's oncology pipeline, potentially strengthening its competitive position in precision cancer treatment.
Negative Factors
Negative Revenue Growth
The negative revenue growth trend indicates a slowing top-line trajectory, which could hinder long-term expansion and market competitiveness.
Read all positive and negative factors
Positive Factors
Negative Factors
Oncology Innovation
The initiation of a Phase I trial for a PSMA-targeting radiopharmaceutical enhances Fosun Pharma's oncology pipeline, potentially strengthening its competitive position in precision cancer treatment.
Read all positive factors
Shanghai Fosun Pharmaceutical (Group) Co (2196) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$74.89B
Dividend Yield1.69%
Average Volume (3M)8.63M
Price to Earnings (P/E)14.2
Beta (1Y)1.11
Revenue Growth-1.12%
EPS Growth76.16%
CountryHK
Employees40,557
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.36
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)0.75
Price to Sales (P/S)0.86
P/FCF Ratio530.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$35.30Price Target Upside79.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.47
Revenue Forecast (FY)HK$43.24B
Shanghai Fosun Pharmaceutical (Group) Co Business Overview & Revenue Model
Company Description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Hea...
How the Company Makes Money
Fosun Pharma generates revenue through a diversified business model that encompasses several key streams. The primary revenue source is the sale of pharmaceutical products, including both proprietary and generic medications, which are distributed ...
Shanghai Fosun Pharmaceutical (Group) Co Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.12B | 41.07B | 41.40B | 43.95B | 39.01B | 30.31B |
| Gross Profit | 19.09B | 19.70B | 19.68B | 20.78B | 18.78B | 16.88B |
| EBITDA | 6.33B | 8.60B | 7.55B | 7.87B | 8.70B | 7.23B |
| Net Income | 3.25B | 2.77B | 2.39B | 3.73B | 4.73B | 3.66B |
Balance Sheet | ||||||
| Total Assets | 118.83B | 117.46B | 113.47B | 107.16B | 93.29B | 83.69B |
| Cash, Cash Equivalents and Short-Term Investments | 15.64B | 16.12B | 15.58B | 17.17B | 14.55B | 11.93B |
| Total Debt | 32.21B | 31.70B | 30.28B | 30.25B | 24.25B | 24.01B |
| Total Liabilities | 58.51B | 57.53B | 56.85B | 53.05B | 44.92B | 37.70B |
| Stockholders Equity | 47.40B | 47.26B | 45.68B | 44.58B | 39.19B | 37.00B |
Cash Flow | ||||||
| Free Cash Flow | -766.40M | 66.79M | -1.92B | -1.67B | -1.02B | -1.86B |
| Operating Cash Flow | 4.70B | 4.48B | 3.41B | 4.22B | 3.95B | 2.58B |
| Investing Cash Flow | -1.82B | -3.61B | -3.82B | -4.06B | -3.86B | -4.71B |
| Financing Cash Flow | -3.55B | -1.00B | -1.34B | 4.43B | -831.28M | 1.47B |
Shanghai Fosun Pharmaceutical (Group) Co Technical Analysis
Neutral
19.63
Price Trends
19.95
Negative
20.74
Negative
20.96
Negative
Market Momentum
-0.23
Negative
53.72
Neutral
79.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2196, the sentiment is Neutral. The current price of 19.63 is above the 20-day moving average (MA) of 19.10, below the 50-day MA of 19.95, and below the 200-day MA of 20.96, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 79.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2196.
Shanghai Fosun Pharmaceutical (Group) Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$25.41B | 22.15 | 7.26% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$19.14B | 9.66 | 12.63% | 5.11% | 0.39% | 4.94% | |
70 Outperform | HK$30.92B | 11.61 | 14.53% | 4.09% | -0.45% | 9.00% | |
61 Neutral | HK$35.81B | 6.37 | 7.91% | 2.95% | ― | ― | |
59 Neutral | HK$40.46B | 8.90 | 7.89% | 7.15% | 1.13% | -13.53% | |
53 Neutral | HK$74.89B | 14.15 | 7.02% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.76
4.32
28.00%
HK:3933
The United Laboratories International Holdings
9.70
-4.70
-32.62%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
17.00
0.37
2.21%
HK:1513
Livzon Pharmaceutical Group
27.50
0.72
2.68%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.70
0.65
12.85%
HK:0512
Grand Pharmaceutical Group Limited
7.16
1.20
20.13%
Shanghai Fosun Pharmaceutical (Group) Co Corporate Events
Fosun Pharma Subsidiary’s Erythromycin Injection Application Accepted by Chinese Regulator
Jan 14, 2026
Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application submitted by its subsidiary, Suzhou Erye Pharmaceutical, for Erythromycin Lactobionate for Injection. The chemic...
Fosun Pharma Subsidiary’s Lung Cancer Drug Application Accepted by China Regulator
Jan 8, 2026
Shanghai Fosun Pharmaceutical announced that its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group has had its resubmitted drug registration application for Foritinib Succinate Capsules accepted by China’s National Medical Products Adm...
Fosun Pharma Subsidiary Launches Phase I Trial of PSMA Radiopharmaceutical for Advanced Prostate Cancer
Dec 30, 2025
Shanghai Fosun Pharmaceutical’s subsidiary Chengdu Xingrui Jingxuan Therapeutics has initiated a Phase I clinical trial in mainland China for SRT-007, a theranostic radiopharmaceutical targeting PSMA-positive metastatic castration‑resi...
Fosun Pharma Subsidiary Gains Approval for Ketoprofen Patch Clinical Trials
Dec 12, 2025
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received approval from the National Medical Products Administration to begin Phase III clinical trials for a Ketoprofen Patch in China. This dru...
Fosun Pharma’s Subsidiary Gains Approval for New Drug
Dec 10, 2025
Shanghai Fosun Pharmaceutical announced that its subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Foscarnet Sodium Injection. This approval allows the...
Fosun Pharma Subsidiary Gains Approval for Innovative Cancer Drug Trial
Dec 3, 2025
Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Pharma Industrial, has received approval from the National Medical Products Administration to commence a Phase I clinical trial for FXS0887 Tablets, intended for the treatment of a...
Fosun Pharma’s Subsidiary Gains Approval for Heparin Sodium Injection
Dec 2, 2025
Shanghai Fosun Pharmaceutical announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its drug registration application for Heparin Sodium Injection accepted by the National Medical Products Administration. This drug is intend...
Shanghai Fosun Pharmaceutical Announces EGM Results and Director Election
Dec 2, 2025
Shanghai Fosun Pharmaceutical announced the results of its 2025 second extraordinary general meeting, where the election of an executive director was a key agenda item. The meeting, compliant with relevant legal and corporate governance standards,...
Shanghai Fosun Pharmaceutical Announces Board Composition and Committee Roles
Dec 2, 2025
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced the composition of its board of directors, which consists of 12 members, including executive, non-executive, independent non-executive, and employee directors. The announcement also detaile...
Fosun Pharma Announces Strategic Agreements with CQ Pharma and Fosun International
Nov 28, 2025
Shanghai Fosun Pharmaceutical has announced a series of continuing connected transactions, including the CQ Pharma Mutual Supply Framework Agreement, the Framework Tenancy Agreements, and the Fosun International Mutual Supply Framework Agreement. ...
Fosun Pharma’s Pediatric Drug Application Gains Priority Review
Nov 21, 2025
Shanghai Fosun Pharmaceutical announced that its subsidiary’s drug registration application for Luvometinib Tablets, intended for treating pediatric patients with Langerhans cell histiocytosis, has been accepted by China’s National Med...
Fosun Pharma’s Subsidiary Gains Approval for New Drug Application
Nov 18, 2025
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received acceptance for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder by the National Medical ...
Shanghai Fosun Pharmaceutical Schedules 2025 Extraordinary General Meeting
Nov 7, 2025
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on December 2, 2025, in Shanghai. The primary agenda is to elect Mr. Liu Yi as an executive director. Th...
Shanghai Fosun Pharma Announces First Grant Under 2025 A Share Option Scheme
Nov 4, 2025
Shanghai Fosun Pharmaceutical has announced the first grant under its 2025 A Share Option Scheme, issuing 4,535,100 A Share Options to 195 participants. This grant, representing approximately 0.1698% of the company’s total shares, includes c...
Shanghai Fosun Pharmaceutical Announces First Grant Under 2025 H Share RSU Scheme
Nov 4, 2025
Shanghai Fosun Pharmaceutical has announced the first grant under its 2025 H Share Restricted Stock Unit (RSU) Scheme, which was approved by shareholders. The grant involves 195 eligible employees, including key executives, receiving a total of 10...
Fosun Pharma Revises 2025 Transaction Cap to RMB90 Million
Oct 28, 2025
Shanghai Fosun Pharmaceutical has announced a revision of its annual cap for continuing connected transactions under the Fosun International Mutual Supply Framework Agreement for 2025. The adjustment increases the cap from RMB70 million to RMB90 m...
Shanghai Fosun Pharmaceutical Plans Spin-off Listing for Fosun Adgenvax
Oct 28, 2025
Shanghai Fosun Pharmaceutical has announced the proposed spin-off listing of its subsidiary, Fosun Adgenvax, on the Hong Kong Stock Exchange. Fosun Adgenvax specializes in vaccines and has several products approved for marketing in mainland China,...
Shanghai Fosun Pharma Releases 2025 Q3 Report
Oct 28, 2025
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited third quarterly report for 2025, covering the period ending on September 30. The report is prepared in accordance with PRC Accounting Standards and assures stakeholders of ...
Shanghai Fosun Pharmaceutical Subsidiary Gains Drug Registration Approval
Oct 24, 2025
Shanghai Fosun Pharmaceutical announced the approval for drug registration of one of its subsidiaries, which marks a significant milestone in its operational capabilities. This approval is expected to enhance the company’s market position an...
Shanghai Fosun Pharmaceutical Announces EGM Results and Voting Abstentions
Oct 23, 2025
Shanghai Fosun Pharmaceutical announced the results of its 2025 first extraordinary general meeting, where several resolutions were voted on. Key stakeholders, including directors and major shareholders, abstained from voting on resolutions relate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.